Abrasion-Resistant and Award-Winning: New Label for Adrenaline Injector from TEVA
Abrasion-Resistant and Award-Winning:
New Label for Adrenaline Injector from TEVA
Patients with life-threatening allergies constantly carry a life-saving companion with them: an adrenaline autoinjector they can use themselves for an immediate injection to prevent an allergic reaction that may lead to anaphylactic shock. For the emergency drug epinephrine from TEVA, Schreiner MediPharm developed an especially abrasion-resistant Autoinjector-Label. Vital user and product information thus remains perfectly legible over a prolonged period of time. In November 2019, the novel label won an award in the Competition of the North American Tag & Label Manufacturers (TLMI).
Epinephrine is a prescription drug that can be used to treat life-threatening allergic emergencies. The adrenaline is offered by TEVA, a worldwide leader in generic drugs and specialty medicines, in single-dose, prefilled disposable autoinjectors.
For this injector, Schreiner MediPharm developed a label with abrasion- and scratch-resistant reverse printing. It is particularly resistant against chemical and mechanical impacts which the autoinjector is exposed to while being carried, for instance, in a purse or backpack. The special material construction and design that is precisely adapted to the sophisticated shape of the autoinjector ensure that the marking label reliably adheres to the device. Consequently, the vital information about the product and its use is perfectly legible and always readily available. There is no need for an additional cover protecting the label against abrasion or separation. This means less waste and a smaller environmental footprint. For product and patient safety, the label has a perforation: it clearly and irreversibly indicates any first opening of the cap and potential tampering attempt.
In 2019, the North American Tag and Label Manufacturers Institute (TLMI) recognized the TEVA Autoinjector-Label in its annual awards competition. Schreiner MediPharm’s product development won second place in the “Multi-Process” category.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com